ClinicalTrials.gg
CompletedNCT03491904FACT DEVICEUpdated Mar 3, 2021

To Assess the Patients' Ability to Self-Administer Fasinumab

A Phase 1 interventional study of Fasinumab AI and Fasinumab PFS in Osteoarthritis, Knee and Osteoarthritis, Hip, sponsored by Regeneron Pharmaceuticals. Completed at 23 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-03.

Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Jan 2020, 6 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 796 studies in Osteoarthritis, Knee with a site in United States — 109 open to participants now, 153 under way, 15 of them phase 3. Osteoarthritis, Knee · United States.

Enrollment
273rd of 691
100 · median 72
Started
2019
with 52 others
Phase 1
38 of 796
4 open now
Registered
399th of 796
by date

Among the 796 studies in Osteoarthritis, Knee with a site in United States, this one is the 273rd largest by enrollment of the 691 interventional ones that give a count, is one of 53 that started in 2019, is one of 38 in phase 1, and was the 399th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

109 of the 796 studies in Osteoarthritis, Knee with a site in United States are open now. Recruiting first, the newest first:

104 more — sign in →

All 109 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 385 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 114 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 796 studies in Osteoarthritis, Knee with a site in United States, or all of them as a file.
02

Study summary

The primary objective is to demonstrate that the auto-injector(AI) is suitable to be used to administer fasinumab at home by patients or their caregivers, as measured by collecting 12 weeks of actual-use data on the technical performance of the device.

The secondary objectives of the study are:

  • To evaluate the successful injection of fasinumab by patients or their caregivers using the AI in an unsupervised setting
  • To evaluate patient/caregiver satisfaction with the AI for fasinumab injection in an unsupervised setting
  • To evaluate exposure in serum for fasinumab administered by patients or their caregivers using an AI in an unsupervised setting, or fasinumab administered by study staff using a PFS that has been used in the phase 3 program
  • To characterize the safety, tolerability, and immunogenicity of fasinumab administered by patients or their caregivers using an AI in an unsupervised setting, or fasinumab administered by study staff using a PFS that has been used in the phase 3 program
03

Conditions studied

  • Osteoarthritis, Knee
  • Osteoarthritis, Hip
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. A clinical diagnosis of Osteoarthritis (OA) of the knee or hip based on the American College of Rheumatology criteria with radiologic evidence of OA (K-L score ≥2 for the index joint) at the screening visit
  2. Moderate-to-severe pain in the index joint defined as a WOMAC average pain subscale score of ≥4 at both the screening and randomization visits
  3. Willing to discontinue current pain medications and to adhere to study requirements for rescue treatments
  4. A history of at least 12 weeks of analgesic use for pain due to OA of the knee or hip
  5. History of regular use of analgesic medications for OA pain (defined as an average of 4 days per week over the 4 weeks prior to the screening visit), including NSAIDs, selective cyclooxygenase 2 inhibitors, opioids, paracetamol/acetaminophen, or combinations thereof

Key Exclusion Criteria:

  1. History or presence at the screening visit of non-OA inflammatory joint disease (eg,rheumatoid arthritis, lupus erythematosus, psoriatic arthritis, pseudo-gout, gout, spondyloarthropathy, polymyalgia rheumatica, joint infections within the past 5 years), Paget's disease of the spine, pelvis or femur, neuropathic disorders, multiple sclerosis, fibromyalgia, tumors or infections of the spinal cord, or renal osteodystrophy
  2. History or presence on imaging of arthropathy (osteonecrosis, subchondral insufficiency fracture, rapidly progressive OA type 1 or type 2), stress fracture, recent stress fracture, neuropathic joint arthropathy, hip dislocation (prosthetic hip dislocation is eligible), knee dislocation (patella dislocation is eligible), congenital hip dysplasia with degenerative joint disease, extensive subchondral cysts, evidence of bone fragmentation of collapse, or primary tumor with the exception of chondromas or pathologic fractures during the screening period
  3. Trauma to the index joint within 3 months prior to the screening visit
  4. Signs or symptoms of carpal tunnel syndrome within 6 months of screening
  5. Patient is not a candidate for MRI

Note: Other protocol defined Inclusion/Exclusion criteria apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Auto-injector (AI)

    Drug: Fasinumab AI

  • Experimental
    Prefilled syringe (PFS)

    Drug: Fasinumab PFS

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of device-associated product technical failure (PTF) for the AI based on the total number of fasinumab injections administered by patients/caregivers in an unsupervised setting

    Time frame: Baseline to Week 16

Secondary outcomes

  1. Proportion of successful fasinumab injections administered by patients or their caregivers using an AI in an unsupervised setting (per patient report)

    Time frame: Baseline to Week 16

  2. Number of AI associated product technical complaint (PTCs)

    Time frame: Baseline to Week 16

  3. Number of validated AI associated PTFs

    Time frame: Baseline to Week 16

  4. Number of patients with an AI associated PTC

    Time frame: Baseline to Week 16

  5. Number of AI use-related errors

    Including but not limited to improper storage, inappropriate use of the device, dosing schedule mistakes, and user handling mistakes

    Time frame: Baseline to Week 16

  6. Patient satisfaction with the AI as assessed using the Self-Injection Assessment Questionnaire (SIAQ)

    Time frame: Baseline to Week 16

  7. Number of participants who experience Adjudicated arthropathy (AA)

    As confirmed by independent adjudication

    Time frame: Through week 36

  8. Number of participants who experience Destructive arthropathy (DA)

    As confirmed by independent adjudication

    Time frame: Through week 36

  9. Number of participants who experience treatment-emergent adverse events (TEAEs)

    Time frame: Through week 16

  10. Number of participants who experience sympathetic nervous system dysfunction

    Time frame: Through week 36

  11. Number of participants who experience peripheral sensory adverse events (AEs) that require a neurology or other specialty consultation

    Time frame: Through week 36

  12. Number of participants who experience all-cause Joint replacement (JR)s

    Time frame: Through week 36

  13. Number of participants who experienced JR at the telephone survey

    Time frame: 52 weeks after last dose of study drug

  14. Maximum observed drug concentration (Cmax)

    Time frame: Up to 36 weeks

  15. Area under the curve from the time of dosing to the end of dosing interval (AUC)

    Time frame: Up to 36 weeks

  16. Geometric mean ratio of Cmax and AUC for the AI device (CI) of the geometric mean ratio

    Time frame: Up to 36 weeks

  17. Geometric mean ratio of Cmax and AUC for the PFS device (CI) of the geometric mean ratio

    Time frame: Up to 36 weeks

  18. Incidence of anti-drug antibody (ADA)

    Time frame: Up to 36 weeks

07

Study locations

23 sites
  • Regeneron Research Facility
    Gilbert, Arizona 85297, United States
  • Regeneron Research Facility
    Glendale, Arizona 85307, United States
  • Regeneron Research Facility
    Los Angeles, California 90029, United States
  • Regeneron Research Facility
    Wheat Ridge, Colorado 80033, United States
  • Regeneron Research Facility
    Ocala, Florida 34471, United States
  • Regeneron Research Facility
    Orlando, Florida 32822, United States
  • Regeneron Research Facility
    Pinellas Park, Florida 33781, United States
  • Regeneron Research Facility
    Port Orange, Florida 32127, United States
  • Regeneron Research Facility
    Atlanta, Georgia 30342, United States
  • Regeneron Research Facility
    West Des Moines, Iowa 50265, United States
  • Regeneron Research Facility
    Wichita, Kansas 67205, United States
  • Regeneron Research Facility
    Lexington, Kentucky 40503, United States
  • Regeneron Research Facility
    Lexington, Kentucky 40504, United States
  • Regeneron Research Facility
    Jamaica, New York 11432, United States
  • Regeneron Research Facility
    Statesville, North Carolina 28625, United States
  • Regeneron Research Facility
    Wilmington, North Carolina 28401, United States
  • Regeneron Research Facility
    Oklahoma City, Oklahoma 73114, United States
  • Regeneron Research Facility
    Bristol, Tennessee 37620, United States
  • Regeneron Research Facility
    Knoxville, Tennessee 37938, United States
  • Regeneron Research Facility
    Dallas, Texas 75231, United States
  • Regeneron Research Facility
    Houston, Texas 77024, United States
  • Regeneron Research Facility
    Houston, Texas 77089, United States
  • Regeneron Research Facility
    Houston, Texas 77804, United States
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Individual de-identified participant data will be made available once the indication has been approved by a regulatory body, if there is participant consent and there is not a reasonable likelihood of participant re-identification

Access criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in Jan 2020, 11 months.

Of 34 industry-sponsored phase 1 interventional studies under Osteoarthritis, Knee, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 21. This study's 11 months is below that.

Counting every sponsor, half of 61 studies reached it within 20 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2018
First posted
Apr 9, 2018
StartActual
Jan 23, 2019
Primary completionActual
Jan 15, 2020
CompletionActual
Dec 15, 2020
Last update
Mar 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03491904
Responsible party
Sponsor
First posted
Apr 9, 2018
Start date
Jan 23, 2019
Primary completion
Jan 15, 2020
Completion
Dec 15, 2020
Last update
Mar 3, 2021

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fasinumab

Start the discussion